StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for AQST yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $4.17 | $4.13 | -0.84% | 2.7M |
| 05-19 | $4.07 | $4.09 | +0.49% | 1.6M |
| 05-20 | $4.10 | $4.17 | +1.71% | 1.2M |
| 05-21 | $4.11 | $4.23 | +2.92% | 1.4M |
| 05-22 | $4.26 | $4.16 | -2.35% | 0.4M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $14.45M | $44.55M | $31.53M | $18.72M |
Operating Income | $-4.20M | $-71.05M | $-42.21M | $-30.73M |
Net Income | $-8.06M | $-83.78M | $-51.92M | $-13.55M |
EPS (Diluted) | $-0.07 | $-0.78 | $-0.51 | $-0.37 |
Total Assets | $141.13M | $160.43M | $163.56M | $93.70M |
Total Liabilities | $175.18M | $194.09M | $167.67M | $166.29M |
Cash & Equivalents | $110.73M | $121.17M | $129.06M | $60.54M |
Free Cash Flow OCF − CapEx | $-14.86M | $-52.99M | $-44.44M | $-31.56M |
Shares Outstanding | 124.28M | 122.04M | 121.66M | 99.35M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.